Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17060173 | 0.90 | — | — | |
| SCHEMBL2234345 | 0.89 | SLC9A1 (0.32) | MAPTKDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL17060167 | 0.89 | KDM4E (0.33) | MAPTKDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL17060098 | 0.86 | — | — | |
| SCHEMBL17060078 | 0.86 | OPRK1 (0.31) | — | |
| SCHEMBL17096505 | 0.85 | PTGS1 (0.34) | — | |
| Hydrochloric Acid SCHEMBL17096933 | 0.85 | MAPT (0.32) | MAPTKDM4ESMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL17096968 | 0.84 | GSK3B (0.34) | — | |
| SCHEMBL17096381 | 0.84 | MEN1 (0.32) | MAPTSMN1; SMN2ALDH1A1HPGDMEN1 | |
| SCHEMBL17060055 | 0.83 | PTGS1 (0.33) | MAPTKDM4ESMN1; SMN2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9902749-B2 | Metallocene complex and olefin polymerization method | JAPAN POLYPROPYLENE CORPORATION (JP) | 2018-02-27 | — | — | US | disclosed |
| US-20150266914-A1 | METALLOCENE COMPLEX AND OLEFIN POLYMERIZATION METHOD | JAPAN POLYPROPYLENE CORPORATION (JP) | 2015-09-24 | — | — | US | disclosed |
| CN-104781270-A | Metallocene complexes and olefin polymerization process | JAPAN POLYPROPYLENE CORP | 2015-07-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266914-A1 | METALLOCENE COMPLEX AND OLEFIN POLYMERIZATION METHOD | POR, OPRM1, ALOX12 | MAPT 2002/4885KDM4E 4392/4885SMN1; SMN2 2246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.